PHASQ — PhaseBio Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$3.73m
- $10.83m
PhaseBio Pharmaceuticals Inc expected to post a loss of 46 cents a share - Earnings Preview
PhaseBio rises on European licensing deal for blood clotting drug
Brief: Phasebio Announces European Licensing Agreement With Alfasigma S.P.A For Commercialization Of Bentracimab
U.S. RESEARCH ROUNDUP- Amgen, Lion Electric, UiPath
PhaseBio Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: PhaseBio Pharmaceuticals Reports Qtrly Net Loss Per Common Share, Basic And Diluted $0.87
U.S. RESEARCH ROUNDUP- Coca-Cola, Lam Research, Valvoline
Brief: Avidity Partners Management Reports 9.4% Passive Stake In Phasebio Pharmaceuticals
U.S. STOCKS ON THE MOVE-Upstart, ContraFect, Evolving Systems
PhaseBio falls on $56 mln equity raise
Brief: PhaseBio Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
Brief: Phasebio Pharmaceuticals Says Commenced An Underwritten Public Offering Of Shares Of Common Stock
U.S. STOCKS ON THE MOVE-PhaseBio, Lizhi, HF Foods
-PhaseBio: Up as Needham raises PT to Street high
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:43 AM
Brief: Phasebio Reports Q4 And FY20 Financial Results
Brief: PhaseBio Pharmaceuticals Says Co Obligated To Buy Minimum Of About $14 Mln Of Batches Of Product From BioVectra
Brief: PhaseBio Pharmaceuticals Says Entered Into Supply Agreement With BioVectra
Brief: PhaseBio Presents Data From Phase 1B/2A Trial Of Pemziviptadil To Treat Pulmonary Arterial Hypertension At Pulmonary Vascular Research Institute Virtual World Congress